S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.16 (-2.90%)
AAPL   122.06 (-2.45%)
MSFT   227.56 (-2.70%)
FB   255.41 (-1.39%)
GOOGL   2,011.41 (-2.57%)
TSLA   653.20 (-4.84%)
AMZN   3,005.00 (-2.89%)
NVDA   512.19 (-4.49%)
BABA   236.27 (+0.79%)
CGC   33.24 (-5.70%)
GE   13.44 (+3.54%)
MU   89.11 (-2.17%)
NIO   41.53 (-4.07%)
AMD   80.86 (-3.89%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   520.70 (-4.95%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:ORMP

Oramed Pharmaceuticals Stock Forecast, Price & News

$8.80
0.00 (0.00 %)
(As of 03/3/2021 04:39 PM ET)
Add
Compare
Today's Range
$8.50
Now: $8.80▼
$8.92
50-Day Range
$4.31
MA: $8.10▼
$11.33
52-Week Range
$2.40
Now: $8.80▼
$11.71
Volume430,625 shs
Average Volume722,371 shs
Market Capitalization$258.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Oramed Pharmaceuticals logo

Headlines

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
January 21, 2021 |  finance.yahoo.com
We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
January 8, 2021 |  finance.yahoo.com
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
January 7, 2021 |  finance.yahoo.com
Oramed Reports Positive First in Human Data from Oral Leptin Study
December 23, 2020 |  finance.yahoo.com
ORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical Studies
December 10, 2020 |  finance.yahoo.com
Oramed launches late-stage NASH study with oral insulin
December 4, 2020 |  seekingalpha.com
Is Oramed Pharmaceuticals (ORMP) A Good Stock To Buy Now?
December 4, 2020 |  finance.yahoo.com
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
December 2, 2020 |  finance.yahoo.com
Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?
December 1, 2020 |  marketwatch.com
Oramed Pharma screens first patients under its Phase 3 oral insulin trial, shares +8%
November 24, 2020 |  seekingalpha.com
Oramed Initiates Phase 3 Trial of Oral Insulin
November 24, 2020 |  finance.yahoo.com
Oramed Pharmaceuticals Inc. Common Stock (ORMP)
November 19, 2020 |  nasdaq.com
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
November 12, 2020 |  prnewswire.com
Oramed to Present at H.C. Wainwright 6th Annual Israel Conference
November 10, 2020 |  finance.yahoo.com
Oramed Pharmaceuticals'(NASDAQ:ORMP) Share Price Is Down 71% Over The Past Three Years.
November 9, 2020 |  finance.yahoo.com
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
October 28, 2020 |  finance.yahoo.com
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
October 27, 2020 |  finance.yahoo.com
Oramed updates on Phase 3 oral insulin studies: protocols submitted to FDA
October 16, 2020 |  seekingalpha.com
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
October 16, 2020 |  finance.yahoo.com
ORMP: Advancing Toward Phase 3 Program For ORMD-0801
September 22, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
Previous Symbol
CUSIPN/A
CIK1176309
Webwww.oramed.com
Phone844-967-2633
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio8.93
Quick Ratio8.93

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.71 million
Price / Sales95.37
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.40 per share
Price / Book6.29

Profitability

EPS (Most Recent Fiscal Year)($0.56)
Net Income$-11,510,000.00
Net Margins-424.76%
Return on Equity-45.93%
Return on Assets-30.33%

Miscellaneous

Outstanding Shares29,370,000
Market Cap$258.46 million
Next Earnings Date4/5/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

1.32 out of 5 stars

Medical Sector

706th out of 1,968 stocks

Pharmaceutical Preparations Industry

346th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$8.80
0.00 (0.00 %)
(As of 03/3/2021 04:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

Is Oramed Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Oramed Pharmaceuticals?

Wall Street analysts have given Oramed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oramed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,820,000 shares, an increase of 45.6% from the January 28th total of 1,250,000 shares. Based on an average daily trading volume, of 894,500 shares, the days-to-cover ratio is presently 2.0 days. Currently, 7.6% of the shares of the stock are short sold.
View Oramed Pharmaceuticals' Short Interest.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for Oramed Pharmaceuticals.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its earnings results on Wednesday, January, 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.09. The biotechnology company had revenue of $0.67 million for the quarter. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 45.93% and a negative net margin of 424.76%.
View Oramed Pharmaceuticals' earnings history.

How has Oramed Pharmaceuticals' stock price been impacted by COVID-19?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ORMP stock has increased by 165.9% and is now trading at $8.80.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ORMP?

4 brokerages have issued 12 month price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $11.00 to $17.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $13.33 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Mr. Nadav Kidron, Pres, CEO & Exec. Director (Age 47, Pay $1.2M)
  • Mr. Avraham Gabay, CFO, Treasurer & Sec. (Age 36, Pay $191.06k)
  • Mr. Joshua Hexter, Chief Operating & Bus. Officer (Age 51, Pay $267.82k)
  • Dr. Miriam Kidron, Chief Scientific Officer & Director (Age 81, Pay $389.19k)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Who are some of Oramed Pharmaceuticals' key competitors?

Some companies that are related to Oramed Pharmaceuticals include Veru (VERU), Enanta Pharmaceuticals (ENTA), Vanda Pharmaceuticals (VNDA), Karyopharm Therapeutics (KPTI), G1 Therapeutics (GTHX), Epizyme (EPZM), Dynavax Technologies (DVAX), Vectura Group (VEGPF), Cara Therapeutics (CARA), Syndax Pharmaceuticals (SNDX), MannKind (MNKD), Humanigen (HGEN), Lexicon Pharmaceuticals (LXRX), Phibro Animal Health (PAHC) and ESSA Pharma (EPIX).
View all of ORMP's competitors.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.27%), BlackRock Inc. (0.26%), Squarepoint Ops LLC (0.10%), LMR Partners LLP (0.08%), Jane Street Group LLC (0.07%) and LPL Financial LLC (0.05%).
View institutional ownership trends for Oramed Pharmaceuticals.

Which major investors are selling Oramed Pharmaceuticals stock?

ORMP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Jane Street Group LLC, and LMR Partners LLP.
View insider buying and selling activity for Oramed Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Oramed Pharmaceuticals stock?

ORMP stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, LPL Financial LLC, HighTower Advisors LLC, and Oppenheimer & Co. Inc..
View insider buying and selling activity for Oramed Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $8.80.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals has a market capitalization of $258.46 million and generates $2.71 million in revenue each year. The biotechnology company earns $-11,510,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

Where are Oramed Pharmaceuticals' headquarters?

Oramed Pharmaceuticals is headquartered at 1185 AVENUE SUITE 228, NEW YORK NY, 10036.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.